Research Disclaimer: This article is for informational and educational purposes only. SARMs are sold strictly as research compounds and are not intended for human consumption.
SARMs vs Prohormones: A Detailed Comparison
SARMs and prohormones both target the androgen receptor pathway, but they do it in fundamentally different ways with very different risk profiles. If you’re trying to decide between them — or just want to understand the differences — here’s the full breakdown.
What Are Prohormones?
Prohormones are precursor compounds that convert into active anabolic hormones once inside your body. They’re essentially inactive on their own — they rely on enzymatic conversion (typically in the liver) to become active steroids.
Examples include:
- 1-Androsterone — converts to 1-testosterone
- 4-Androsterone — converts to testosterone
- DHEA — converts to testosterone and oestrogen
- Epistane — technically a designer steroid, often sold as a prohormone
The original generation of prohormones (Superdrol, Halodrol, etc.) were banned in the US under the Designer Anabolic Steroid Control Act of 2014. What’s sold as “prohormones” today are mostly DHEA derivatives with weaker conversion rates.
How SARMs Differ Mechanistically
The fundamental difference:
- Prohormones convert into actual steroids in your body. Once converted, they behave exactly like steroids — binding non-selectively to androgen receptors throughout all tissues.
- SARMs bind directly to androgen receptors with tissue selectivity. They preferentially activate receptors in muscle and bone while having reduced activity in prostate, liver, and skin.
This is why SARMs were developed in the first place — to get the anabolic benefits without the systemic androgenic effects.
Head-to-Head Comparison
| Factor | SARMs | Prohormones |
|---|---|---|
| Mechanism | Direct selective AR binding | Enzymatic conversion to steroids |
| Tissue selectivity | High | None (act as steroids once converted) |
| Liver toxicity | Minimal at standard doses | Significant (methylated, liver-processed) |
| Testosterone suppression | Mild to moderate | Severe (full HPTA shutdown common) |
| Aromatisation | No | Yes (many convert to oestrogen) |
| Gynecomastia risk | No | Yes (oestrogen-related) |
| Hair loss risk | Very low | Moderate to high |
| Acne risk | Very low | Moderate to high |
| Prostate effects | Minimal (selective) | Significant (non-selective) |
| Muscle gains | Moderate (2-5kg) | Moderate to high (3-7kg) |
| Administration | Oral (no liver methylation needed) | Oral (methylated for bioavailability) |
| PCT required | Yes (milder protocol) | Yes (aggressive protocol needed) |
| Clinical trials | Phase I-II in humans | Very limited formal research |
| Legal status (UK) | Legal as research chemicals | Grey area / mostly discontinued |
The Liver Problem
This is arguably the biggest practical difference. Prohormones must be 17-alpha-alkylated (methylated) to survive first-pass liver metabolism. This methylation is what makes them orally bioavailable — but it also makes them hepatotoxic.
SARMs, by contrast, are orally bioavailable without methylation. Their molecular structure allows absorption without the liver stress that defines prohormone use.
Typical prohormone cycles require liver support supplements (TUDCA, NAC, milk thistle) as standard. With SARMs at recommended doses, liver impact is generally subclinical.
The Oestrogen Problem
Many prohormones convert not just to anabolic hormones but also to oestrogen via aromatase enzymes. This means prohormone users often need:
- Aromatase inhibitors (AIs) during cycle
- SERMs for gynecomastia prevention
- Careful oestrogen management throughout
SARMs don’t aromatise. Period. No oestrogen conversion means no gynecomastia risk, no bloating from oestrogen-related water retention, and no need for AIs.
Effectiveness
Stronger prohormones (the ones that are now mostly banned) were more potent than SARMs for raw muscle gain. The current generation of legal prohormones (mostly DHEA derivatives) are actually weaker than top-tier SARMs like RAD-140 or LGD-4033, with more side effects per unit of muscle gained.
That’s the trade-off that’s shifted the market toward SARMs — better results-to-risk ratio with the currently available compounds.
PCT Requirements
Both require post-cycle therapy, but the severity differs:
- SARMs PCT: Typically Nolvadex 20-40mg/day for 4 weeks. Some mild SARMs (Ostarine at low doses) may not require PCT at all. See our PCT guide.
- Prohormone PCT: Usually requires both a SERM (Nolvadex or Clomid) AND an AI, often for 4-6 weeks. More aggressive protocols because suppression is deeper.
The Verdict
The shift from prohormones to SARMs in the research community wasn’t accidental. SARMs offer:
- Better tissue selectivity (fewer systemic side effects)
- No liver methylation required (dramatically less hepatotoxicity)
- No aromatisation (no oestrogen management needed)
- Actual clinical trial data (prohormones have almost none)
- Milder suppression and easier recovery
- Clear legal status in the UK
Prohormones essentially give you steroid-like side effects with sub-steroid results. SARMs give you milder results than steroids with significantly fewer side effects. For most researchers, that’s a much better trade.
For more comparisons: SARMs vs Steroids | Are SARMs Safe?
